$GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Healthcare
Sector
Biotechnology
Industry
Thomas D. Zindrick
CEO
24
Employees
$2.99
Current Price
$106.54M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $34,898.40 | 12,000 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $34,898.40 | 12,000 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $34,898.40 | 12,000 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 7 | $77,889.83 | 26,470 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 7 | $77,889.83 | 26,470 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Smither John W Director | Sale | 12,000 | $2.91 | $34,898.40 | View Details |
| Jun 3, 2026 | Smalling Ralph Head of Regulatory | Sale | 192 | $2.93 | $562.56 | View Details |
| Jun 1, 2026 | Thomas John Director | Sale | 10,000 | $2.98 | $29,801.00 | View Details |
| May 11, 2026 | Yu Yong Chief Scientific Officer | Sale | 605 | $2.97 | $1,798.42 | View Details |
| May 11, 2026 | Cappello Joseph Chief Technical Officer | Sale | 605 | $2.97 | $1,799.39 | View Details |
| May 11, 2026 | Zindrick Thomas President and CEO | Sale | 2,798 | $2.94 | $8,225.56 | View Details |
| May 11, 2026 | Smalling Ralph Head of Regulatory | Sale | 270 | $2.98 | $804.49 | View Details |
18 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.22
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ create a free account to see 12 months of history